Find trials
Search tips

A Study of Tumor DNA Mutations in the Peripheral Blood from Patients who have Cholangiocarcinoma

Overview

About this study

The purpose of this study is to investigate the usefulness of identifying DNA mutations in circulating tumor cells and cfDNA from the peripheral blood of patients with cholangiocarcinoma. The future plan is to compare DNA mutations detected from peripheral blood (the research) with clinical results from tumor tissue.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria: 

  • Adult, age ≥ 18
  • Patients with active disease of intrahepatic, perihilar, distal CCA with histologic confirmation
  • Patients whose clinical provider orders cancer tissue mutation profiling test for clinical care

Exclusion Criteria: 

  • Females who are pregnant or attempting to become pregnant
  • Patient with significant anemia (Hemoglobin <7g/dL)

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Mitesh Borad, M.D.

Closed for enrollment

Contact information:

Meline Arzumanyan M.S.

(480) 342-2082

Arzumanyan.Meline@mayo.edu

Rochester, Minn.

Mayo Clinic principal investigator

Lewis Roberts, M.B., Ch.B., Ph.D.

Closed for enrollment

Contact information:

Nasra Giama D.N.P., R.N.

(507) 538-0097

Giama.Nasra@mayo.edu

More information

Publications

Publications are currently not available

More about research at Mayo Clinic

.
CLS-20492361

Mayo Clinic Footer